Holland & Knight Represents Savara in $100M Underwritten Common Stock Offering
July 04, 2024
July 04, 2024
DENVER, Colorado, July 4 -- Holland and Knight, a law firm, issued the following news release:
Holland & Knight advised Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, in connection with a $100 million underwritten common stock offering. The offering was priced on June 27 and announced on June 28.
The offering included the following investors: Bain Capital Life Sciences, Farallon Capital Management, Frazie . . .
Holland & Knight advised Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, in connection with a $100 million underwritten common stock offering. The offering was priced on June 27 and announced on June 28.
The offering included the following investors: Bain Capital Life Sciences, Farallon Capital Management, Frazie . . .